Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SOPH vs DRIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SOPH Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

SOPH Overall Winner 6-Pillar Tally: SOPH 4 – 1 DRIO (1 Tie) Matrix Metrics: SOPH 7 – 3 DRIO

As of Nov 20, 2026, SOPHiA GENETICS SA (SOPH) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SOPH carries a Unified Composite Score of 55.4/100 (HOLD) at $6.23 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin).

  • Technical & Structure Timing Caution: SOPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SOPH vs DRIO
SOPH NASDAQ Head-to-Head Winner
SOPHiA GENETICS SA Ordinary Shares
Services-Computer Processing & Data Preparation
$6.23
-6.74% 1D
Market Cap $572.2M
TTM Revenue $91M
Forward P/E N/M
Beta / 30D Vol 1.46β · 82% Vol
Unified Composite Score
55.4 / 100 HOLD
Tech 40.0 Fund 53.0 Flow 58.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.1%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $7.37 · SMA50: $7.56
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (SOPH 4 – 1 DRIO)

Columns: Metric · SOPH · DRIO
1. Valuation Multiples DRIO
Forward P/E N/M 10.6x
Trailing P/E N/M 10.6x
PEG Ratio N/M N/M
EV / Revenue 5.9x 0.8x
2. Growth & Scale SOPH
Revenue Growth (YoY) +24.7% +6.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $91M $21M
Market Cap $572.2M $16.3M
3. Profitability & Quality SOPH
Gross Margin 66.4% 61.3%
Operating Margin -81.0% -142.7%
Net Profit Margin -89.2% -159.9%
Return on Equity (ROE) -125.7% -46.6%
4. Balance Sheet & Cash Flow SOPH
Cash Generation (TTM) -$51M -$28M EBITDA
Cash Flow Margin -55.8% -132.8% EBITDA Mgn
Net Cash / Leverage $33M Net Cash $6.37 Book/Sh · -46.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SOPH
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 58.5% (14th %ile) N/A (N/A)
Put/Call OI Skew 1.50x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SOPH (7) vs DRIO (3)
Institutional Metric SOPH DRIO Criterion Row Edge
Market Capitalization
Scale
$572.2M $16.3M Larger Scale SOPH
Trailing P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Forward P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+24.7% +6.1% Higher Growth SOPH
Operating Margin (TTM)
Profitability
-81.0% -142.7% Higher Margin SOPH
Net Profit Margin
Profitability
-89.2% -159.9% Higher Margin SOPH
Return on Equity (ROE)
Capital Efficiency
-125.7% -46.6% Higher ROE DRIO
52-Week Range Position
Momentum
47% ($4–$9) 2% ($1–$15) Stronger Trend SOPH
Beta / 30D Volatility
Risk Regime
1.46β · 82% Vol 0.45β · 182% Vol Lower Realized Risk SOPH
Unified Institutional Score
Composite Signal
55.4 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite SOPH
Trailing 12M Revenue (USD)
Operating Scale
$91M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.4% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.9x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$51M ($33M Net Cash) -$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SOPH +49.66 pp
SOPH: -11.63% · DRIO: -61.29%
3M Horizon SOPH +55.42 pp
SOPH: -26.27% · DRIO: -81.69%
6M Horizon SOPH +110.87 pp
SOPH: +27.66% · DRIO: -83.21%
1Y Horizon SOPH +145.93 pp
SOPH: +55.36% · DRIO: -90.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SOPH vs DRIO. Trailing 12-month operating profitability (SOPH -81.0% vs DRIO -142.7%) and valuation multiples (SOPH N/M vs DRIO 10.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SOPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$91M
Gross Margin66.4%
Op. Margin-81.0%
ROE / Fwd P/E-125.7% · N/M
DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SOPH BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 14th %ile
Put/Call OI Skew 1.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SOPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SOPH Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $572.2M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SOPH vs DRIO Key Questions & Quantitative Answers

As of Nov 20, 2026, SOPHiA GENETICS SA (SOPH) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SOPH carries a Unified Composite Score of 55.4/100 (HOLD) at $6.23 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin). Technical & Structure Timing Caution: SOPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SOPH leads the Growth & Scale pillar: SOPH posts +24.7% YoY revenue growth and +0.0% YoY earnings growth on $91M TTM revenue (66.4% gross margin, -81.0% operating margin), compared with DRIO at +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin). On trailing 12-month operating scale, SOPH generates $91M in USD-normalized revenue versus $21M for DRIO. In operating R&D and SG&A reinvestment, SOPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRIO.

DRIO screens cheaper on headline valuation multiples. SOPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.9x EV/Revenue (-55.8% FCF margin), whereas DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SOPH (-125.7% ROE) versus DRIO (-46.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SOPH carries 58.5% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 82% Vol realized risk). By comparison, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.